Amaia Ugarte1, Alvaro Danza1,2, Guillermo Ruiz-Irastorza1. 1. Autoimmune Diseases Research Unit, Department of Internal Medicine, Biocruces Health Research Institute, Hospital Universitario Cruces, University of The Basque Country, Bizkaia, The Basque Country, Spain. 2. Department of Clinical Medicine, Facultad de Medicina, Hospital Pasteur, Universidad de la República, Montevideo, Uruguay.
Abstract
PURPOSE OF REVIEW: The purpose of this review is highlighting the most recent evidence on the clinical efficacy and toxicity of glucocorticoids and antimalarials in systemic lupus erythematosus (SLE) and provide recommendations on their current use. RECENT FINDINGS: Glucocorticoid toxicity is well known. Recent data confirm the increased risk of infection and damage accrual. An observational study form Hong Kong has seen increased mortality among users of high-dose prednisone regimes. Several studies support the efficacy of medium-low doses and methyl-prednisolone pulses in lupus patients, both with and without nephritis.New data confirm the effects of antimalarials in preventing SLE activity, damage and infections, and in decreasing mortality. New screening recommendations for hydroxychloroquine maculopathy have been recently published. Combining mepacrine and hydroxychloroquine in patients with refractory cutaneous and/or articular lupus activity has proved highly effective. SUMMARY: Universal therapy with hydroxychloroquine should be aimed to patients with SLE without contraindications. Doses greater than 4 mg/kg/day should be avoided and regular eye screening warranted to minimize the risk of macular toxicity. Every effort should be made to reduce the dose of oral glucocorticoids. In moderate-severe flares, pulse methyl-prednisolone are more effective and much less toxic than increasing the oral doses of prednisone.
PURPOSE OF REVIEW: The purpose of this review is highlighting the most recent evidence on the clinical efficacy and toxicity of glucocorticoids and antimalarials in systemic lupus erythematosus (SLE) and provide recommendations on their current use. RECENT FINDINGS: Glucocorticoid toxicity is well known. Recent data confirm the increased risk of infection and damage accrual. An observational study form Hong Kong has seen increased mortality among users of high-dose prednisone regimes. Several studies support the efficacy of medium-low doses and methyl-prednisolone pulses in lupuspatients, both with and without nephritis.New data confirm the effects of antimalarials in preventing SLE activity, damage and infections, and in decreasing mortality. New screening recommendations for hydroxychloroquinemaculopathy have been recently published. Combining mepacrine and hydroxychloroquine in patients with refractory cutaneous and/or articular lupus activity has proved highly effective. SUMMARY: Universal therapy with hydroxychloroquine should be aimed to patients with SLE without contraindications. Doses greater than 4 mg/kg/day should be avoided and regular eye screening warranted to minimize the risk of macular toxicity. Every effort should be made to reduce the dose of oral glucocorticoids. In moderate-severe flares, pulse methyl-prednisolone are more effective and much less toxic than increasing the oral doses of prednisone.
Authors: N Mihaylova; P Chipinski; S Bradyanova; T Velikova; E Ivanova-Todorova; S Chausheva; M Herbáth; D Kalinova; J Prechl; D Kyurkchiev; A I Tchorbanov Journal: Clin Exp Immunol Date: 2019-12-04 Impact factor: 4.330
Authors: Anna Broder; Wenzhu B Mowrey; Ana Valle; Mimi Kim; Candace H Feldman; Kazuki Yoshida; Karen H Costenbader Journal: Arthritis Care Res (Hoboken) Date: 2021-06-13 Impact factor: 5.178
Authors: Víctor Moreno-Torres; Carlos Tarín; Guillermo Ruiz-Irastorza; Raquel Castejón; Ángela Gutiérrez-Rojas; Ana Royuela; Pedro Durán-Del Campo; Susana Mellor-Pita; Pablo Tutor; Silvia Rosado; Enrique Sánchez; María Martínez-Urbistondo; Carmen de Mendoza; Miguel Yebra; Juan-Antonio Vargas Journal: J Clin Med Date: 2021-12-08 Impact factor: 4.241